The domain within your query sequence starts at position 498 and ends at position 1134; the E-value for the DUF3827 domain shown below is 2.4e-282.
WKPQPAGAFQLKTVLQFVSQSDNIQSCRFAQTMEQRLQKAFQDAERKVLSTRSNLTVQIV STSNASQAVTLVYAVGNQSSFLNGTVASSLLSQLSAELVGFYLTYPPLTIAEPLEYPNLD TSETTRDYWVITVLQGVDNSLVGLHNQSFARVMEQRLAQLFMMSQQQGRRFKRATTLGSY TVQMVKMQRVPGPKDPAELTYYTLYNGKPLLGTAAAKILSTIDSQRMALTLHHVVLLQAD PVVKNPPNNLWIIAAVLAPIAVVTIIIIIITAVLCRKNKNDFKPDTMINLPQRAKPVQGF DYAKQHLGQQGADEEVIPVTQETVVLPIPVRDTPQERDTAQDGSAIKTAKSTETRRRSPS ENGSVISNESGKPSSGRRSPQNGMTQQKVTKEESRKRNVTASDEEEGAGLFDSAGKAAAD PFDTSSGSVQLIAIKPSALPVVHPASDRGQESSAALNGEVNKALKQKSDIEHYRNKLRLK AKRKGYYDFPPVEAGKGLAERKMYEKAPKEVEHVLDADPELCAPFAESKNRQQMKNSVYR SRQSLNSPSPGETEMDLLVTRERPRRGIRNSGYDTEPEIIEETNVDRVHEPRGYGRARQA KGHSETSTLSSQPSIDEVRQQMHMLLEEAFSLASAGH
DUF3827 |
![]() |
---|
PFAM accession number: | PF12877 |
---|---|
Interpro abstract (IPR024606): | The function of the proteins in this entry is not currently known, but one of the human proteins ( Q9HCM3 ) has been implicated in pilocytic astrocytomas [ (PUBMED:18974108) (PUBMED:19363522) (PUBMED:19937730) ]. In the majority of cases of pilocytic astrocytomas a tandem duplication produces an in-frame fusion of the gene encoding this protein and the BRAF oncogene. The resulting fusion protein has constitutive BRAF kinase activity and is capable of transforming cells. |
This is a PFAM domain. For full annotation and more information, please see the PFAM entry DUF3827